A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
Licensing deal could enable bundling of antipsychotics with management technology.
The upcoming virtual Esmo congress gives top billing to big pharma immunotherapies.